Published online 2018 April 30.

Serum Levels of Interleukin-4, Interleukin-10 and Interferon- γ in Patients with Chronic Hepatitis B Infection

Seyed Hedayat Hosseini Khorami,^{1,2} Foroogh Nejatollahi,^{1,2,*} and Mohammad Ali Davarpanah^{1,3}

¹Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

²Recombinant Antibody Laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran
³Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

^{*} *Corresponding author*: Foroogh Nejatollahi, Professor of Immunology, Recombinant Antibody Laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. Tel/Fax: +98-7132351575, E-mail: nejatollaf@sums.ac.ir

Received 2017 August 16; Revised 2017 December 25; Accepted 2018 February 19.

Abstract

Background: The imbalance of T-helper (Th) lymphocyte cytokine production plays an important role in the immunopathogenesis of chronic Hepatitis B Virus (HBV) infection. Th1 cytokines are necessary for host antiviral immune response, while Th2 cytokines have an immunomodulatory role.

Objectives: The current study aimed at determining the serum profile of Th1 and Th2 cytokines in patients with chronic HBV infection and to assess the correlation between the levels of the cytokines and ALT level in the patients.

Methods: Sixty patients with chronic hepatitis B and 60 age and gender-matched healthy controls were enrolled in the study. The serum levels of Th1 cytokine, interferon gamma (IFN- γ), Th2 cytokines, IL-4, and IL-10 were measured using the enzyme linked immunosorbent assay (ELISA). The serum ALT level was measured by the Colorimetry method.

Results: The results showed that the level of IL-4 was significantly lower in patients in comparison with the controls (P < 0.05). However, the level of IL-10 was not significantly different in patients and healthy individuals (P > 0.05). The concentration of IFN- γ was significantly higher in patients compared with the healthy controls (P < 0.05). No significant correlation was found between serum levels of IL-4, IL-10 and IFN- γ and nor was it found between the levels of these cytokines and serum ALT level.

Conclusions: The results revealed enhanced Th1 response and reduced Th2 response, which is favored for the formation of a strong immune response and leads to viral elimination. The decrease of IL-4 indicated a lower viral load in the patients. In addition, a non-active disease resulted from the patients' IL10 level showing no significant difference between the patients and the controls. Significant increase of IFN- γ in patients indicated the activation of Th1 cells. The immunological outcome can help in finding better treatment strategies. The results suggest that interferon therapy with low dose can be a helpful strategy. Although the decrease in ALT level was not significantly correlated with an increase in IFN- γ in the patients, the increase of IFN- γ level demonstrated a modulation in hepatocellular damage.

Keywords: HBV Infection, IL-4, IL-10, IFN- γ

1. Background

Hepatitis B is an important cause of morbidity and mortality, worldwide, especially in developing countries, since it accounts for a wide spectrum of liver problems ranging from acute hepatitis to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) (1, 2). According to the report released by the world health organization (WHO) in 2001 and centers for disease control and prevention (CDC) in 2005, the prevalence of chronic hepatitis B infection in Iran was 2% to 7% (3, 4); however, more recent studies have estimated the prevalence of chronic HBV infection as 1.2% and 9.7% in different provinces (5). The prevalence of HBV infection has also been reported among different population groups, including patients with hemophilia (6).

T cell-mediated chronic inflammation leads to necroinflammatory responses during chronic HBV infection. Therefore, T cell-mediated adaptive immunity imposes a "double-edged sword" by decreasing the levels of HBV at the expense of organ injury (7).

During viral infection, various cytokines are involved in both viral clearance and tissue damage mechanisms. While Th1 cytokine profile leads to a cell-mediated immunity and is accompanied by remission, Th2 cytokine response causes the development of persistent lifelong infection. Thus, it can be proposed that the imbalance of pro-

Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

inflammatory Th1 and anti-inflammatory Th2 cytokine synthesis may contribute to the pathogenesis of viral hepatic infections (8, 9).

Recently, in chronic HBV infection, strong long-term viral suppression was achieved through various nucleoside or nucleotide analogs. However, one of the problems with treatment with these analogs is the low rate of HBe seroconversion, even after long-term administration in HBeAg+ subjects (10). Achieving long-term viral eradication could be possible even after cessation of nucleoside or nucleotide analogs, if viral suppression with the analogs were combined with efficient immunotherapies (11). The differences in cytokine pattern of patients from different parts of the world has been reported as well (12-14) and the importance of some cytokines, as indirect markers of T cell activation, has been shown (15). Interleukin-4 and IL-10 as Th2 cytokines and IFN- γ as Th1 cytokine have been measured to determine Th2 and Th1 cell activation in HBV and HCV diseases (16-18). It is important to determine the pattern of patient's cytokine in each area as it can lead to different immunotherapeutic strategies to optimize available antiviral therapies of HBV patients.

According to previous studies, in which the levels of IL-4, IL-10, and IFN- γ were considered as important indirect markers of Th2 and Th1 cell activation (19), this study investigated these three important cytokines to evaluate Th2 and Th1 cell activation in Iranian patients, who are chronically infected with HBV. The relationship between the levels of cytokines and ALT (Alanine transaminase) were also investigated.

2. Objectives

The aim of the current study was to determine the serum level of three important cytokines (IL-4, IL-10, and IFN- γ) in patients with HBV infection in comparison with the levels of these cytokines in healthy controls and to determine the correlation between the levels of cytokines and ALT level.

3. Methods

The study protocol was approved by the local ethics committee of the department of Medical ethics, Shiraz University of Medical Sciences, Shiraz, Iran, and an informed consent form was signed by all participants prior to enrollment in this study. Sixty HBV-infected patients, who were untreated and had no other infections referring to two centers in Shiraz from April 2016 to April 2017, and 60 matched (age and gender) healthy subjects were enrolled in the study. The patients were selected randomly. The HBV infection in the patients had been confirmed by HBV genome detection using polymerase chain reaction following viral quantification by commercial real-time polymerase chain reaction (PCR). The treated patients and those, who had systemic or other diseases, were excluded from the study.

3.1. Blood Sampling and Serum Extraction

Each patient's blood (5 mL) was drawn into a vacutainer tube containing no anticoagulant. After clotting, the samples were centrifuged and the supernatants (serum) were aspirated, aliquoted and stored at 80°C.

3.2. Enzyme-Linked Immunosorbent Assay (ELISA)

The ELISA kit (U-Cytech, bioscience, Netherlands) was used to determine the concentration of cytokines, IL-4, IL-10, and IFN- γ in the patients' sera. Coating antibody (against each of cytokines) was diluted and added to each well of 96-well ELISA plate and incubated at 4°C overnight. After washing the plates with PBST, blocking buffer was added and incubated at 37°C for 1 hour. A mixture of cytokine stabilizing buffer (CSB) and serum, biotinylated detector antibody, Streptavidin-HRP Polymer (SPP conjugate) were added respectively and incubation was done after each step at 37°C for one to two hours. The substrate (TMB solution) was then added and the reaction was stopped after 30 minutes by adding 2M H₂SO₄. The ODs were determined using an ELISA reader. The cytokine standards were also prepared and the concentration of each cytokine (pg/mL) was determined using the standard curve.

3.3. Colorimetry Procedure

The colorimetry procedure was done according to the Colorimetry Kit (Pars Azmoon, Iran) instructions to determine the ALT serum levels. Patient's serum (100 μ L) was added to the first working solution (1000 μ L) (TRIS 100 mmol/L, L-alanine 500 mmol/L and lactate dehydrogenase (LDH) \geq 1200 U/L) and incubated for 5 minutes at 37°C. The second working solution (250 μ L) (2- oxoglutarate 15 mmol/L and NADH 0.18 mmol/L) was then added and mixed. The ODs were read after one, two, and three minutes. The difference between absorbance was determined and the mean of the results was used to determine the average change in absorbance per minute.

3.4. Statistical Analysis

Statistical analysis was performed by the SPSS statistical package version 20 (SPSS Ltd, Woking, Surrey, UK) and 'Mann-Whitney U' test was administered to compare the median level of serum cytokines in patients and controls; Kendall's tau-b correlation coefficient was used to determine the correlations between cytokine levels and ALT levels with cytokine levels.

Variables		Concentration, pg/mL, Median (Min - Max)	P Value
IL-4			0.001
	Patients	6.11 (1.07 - 40.27)	
	Healthy controls	17.76 (11.27 - 67.36)	
IL-10			0.057
	Patients	0.71 (-7.32 - 85.47)	
	Healthy controls	0.51 (0.0 - 13.75)	
IFN- γ	,		0.001
	Patients	1.22 (0.47 - 6.8)	
	Healthy controls	0.84 (0.0 - 12.05)	

Table 1. Descriptive Statistics of Interleukin-4, Interleukin-10 and Interferon- γ Concentration in Chronic Hepatitis B Virus Infected Patients and Healthy Subjects

4. Results

4.1. Serum Level of Cytokines (IL-4, IL-10, IFN- γ) in Patients and Healthy Subjects

Serum levels of IL-4, IL-10, and IFN- γ (pg/mL) in patients with chronic HBV infection and healthy controls are presented in Table 1. The results indicated that the median level of IL-4 was significantly lower in patients compared to healthy controls (6.11 versus 17.76, P=0.001). The median level of IL-10 in patients and controls showed no significant difference (0.71 versus 0.51, P = 0.057). However, the median level of IFN- γ in the patients was significantly higher than that of the healthy subjects (1.22 versus 0.84, P = 0.001).

4.2. Correlation Between Serum Levels of Cytokines, Interleukin-4, Interleukin-10, and Interferon- γ , in Chronic Hepatitis B Virus Infected Patients

No significant correlation was detected between circulating levels of IL-4 and IL-10, IL-4 and IFN- γ , and neither between IL-10 and IFN- γ (P > 0.05) (Figure 1).

4.3. Correlation Between Circulating Cytokines (IL-4, IL-10, and IFN- γ) Levels and ALT in Patients

No significant correlation was detected between circulating levels of IL-4, IL-10, and IFN- γ and ALT level (P > 0.05) (Figure 2).

5. Discussion

Several studies have been performed on the importance of pro-inflammatory Th1 and anti-inflammatory Th2 cytokine profiles in chronic hepatitis B infection. There are contrasting data from these studies regarding the levels of Th1/Th2 cytokines in HBV infection (20). In this study, the researchers assessed the circulating levels of Th1 and Th2





Figure 1. Correlation between serum levels of cytokines; interleukin (IL)-4 and IL-10 (A), IL-4 and interferon (IFN)- γ (B), IL-10 and IFN- γ (C)



Figure 2. Correlation between serum levels of cytokines and ALT; IL-4 and ALT (D), IL-10 and ALT (E), IFN- γ , and ALT (F)

cytokines, IL-4, IL-10, and IFN- γ in chronic HBV-infected patients compared to healthy controls. The results revealed a significant decrease of IL-4 cytokine in chronic HBV patients compared with the healthy individuals. Similar results were obtained by Monsalve-De Castillo et al. (21), who reported a significant decrease in IL-4 levels in both acute and convalescent phases of HBV infection. It has also been reported that the decrease in IL-4 levels could be a consequence of the auto-regulatory mechanism of IL-10. According to Penna et al. (22), levels of IL-4 and IL-5 were increased in acute self-limited hepatitis B infection. A positive correlation was reported between viral load and levels of circulating IL-4 and IL-6 in chronic HBV patients (23). Therefore, decrease of I L-4 evidently indicates a lower viral load in chronic HBV patients.

The current investigation on IL-10 levels showed no significant difference between the median level of IL-10 in patients and controls, which represents a non-active disease. As the patients are in the chronic stage of the disease, this results are in accordance with the disease condition. In some studies, elevated IL-10 levels have been reported in chronic HBV patients. Increase in IL-10 level was shown to be associated with the increase in HBV DNA level (24, 25). Therefore, the increased IL-10 level would represent disease progression. Conde et al. (26) reported that in HBV active disease, the level of IL-10 decreases. Interleukin-10, produced mainly by macrophages, generally acts as an immunosuppressant in chronic viral infection. Significant elevation of serum IL-10 level has been shown in Turkish chronic HBV-infected patients (24) in contrast with the results obtained from the patients in the current study. Interleukin-10 may have an anti-inflammatory role leading towards end-stage liver disease or a pro-inflammatory role leading to self-limiting HBV infection. Some factors, such as viral strain, patients' genetic, and disease phase have important roles in this regard.

Significant increase of IFN- γ in patients compared to controls indicated the activation of Th1 cells. An inverse correlation between the increase of IFN- γ and the decline of HBV load in chronic active hepatitis B patients has been reported (27), which demonstrates the important role of this cytokine against the virus. Some studies have shown that in chronic HBV-infected patients, decrease in Th1 cell activation will lead to the reduction of IFN- γ level. Akpolat et al. (28) reported a lower IFN- γ yet higher IL-4 serum levels in chronic HBV infected patients with decreased Th1 activation compared to controls. The study of Vietnamese HBV infected patients also reported lower levels of IFN- γ than that of the controls, which represents the patients' susceptibility to develop chronic HBV infection (29).

No significant correlation was found between the levels of IL-4 and IL-10, IL-4 and IFN- γ , and IL-10 and IFN- γ .

This means that increase or decrease in one of these cytokines has no significant effect on the increase or decrease of the other cytokine. Similar results were reported by Jegaskanda et al. (30), who measured these correlations in patients with HBV in Australia. Priimagi et al. (31), however, reported a significant positive correlation between IL-10 and IFN- γ in chronic viral hepatitis patients in Estonia.

No significant correlation was found between these three cytokines serum levels with serum ALT level. Similar results were also shown (17, 32) whereas Priimagi et al. (31) reported a significant correlation between IL-10 serum levels and ALT activity in chronic HBV patients. Monitoring ALT is of important value in evaluating hepatocellular damage in patients with chronic hepatitis B virus infection (33). In the present study, although no significant correlation was detected between serum levels of cytokines and ALT level, a decrease in ALT was shown to be due to increasing IFN- γ (Figure 2F). This decrease is not statistically significant; more cases are required to accurately evaluate this correlation. It seems that hepatocellular damage is modulated in patients with higher IFN- γ level.

The importance of viral clearance has led to the development of strategies, including passive immunization and cytokine therapy (34-37). In persistent viral infections, such as HBV infection, cytokine therapy is suggested as a useful immunotherapy (38). Although enhanced Th1 response was found in the current study, in order to improve viral clearance, interferon therapy with a low dose can be regarded as a helpful strategy. The difference in IL-4, IL-10, and IFN- γ levels in patients with chronic HBV infection in different populations could be due to different genetics, viral strains, and disease phases. The primary examination in the current population revealed a high level of IFN- γ and low level of IL-4 in most patients. These changes are indicative of more pronounced activity of Th1 lymphocytes and suppression of Th2 mediator synthesis, which is favored for the formation of immune response and viral elimination.

Acknowledgments

The authors acknowledge the Shiraz University of Medical Science for their financial support. This article was extracted from a thesis written by Seyed Hedayat Hosseini Khorami with grant number 2005.

References

 Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. *Korean J Hepatol.* 2011;17(2):87–95. doi: 10.3350/kjhep.2011.17.2.87. [PubMed: 21757978].

- Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, et al. YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy. *Hepat Mon.* 2015;15(7). e27120. doi: 10.5812/hepatmon.27120v2. [PubMed: 26300928].
- Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403–6. [PubMed: 18193122].
- Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Noorinayer B, Derakhshan F, Chiani M, et al. Molecular epidemiology of hepatitis B virus in Iran. *Clin Microbiol Infect*. 2008;14(9):858–66. doi: 10.1111/j.1469-0691.2008.02053.x. [PubMed: 18844687].
- Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B virus infection in Iran: A systematic review. *Hepatitis monthly*. 2008;8(4):281–94.
- Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. Seroprevalence of hepatitis B and C in patients with hemophilia: A single-centre descriptive study. *Shiraz E Med J.* 2015;16(7). doi: 10.17795/semj24573.
- Ferrari C. HBV and the immune response. *Liver Int*. 2015;35 Suppl 1:121– 8. doi: 10.1111/liv.12749. [PubMed: 25529097].
- Larrubia JR, Benito-Martinez S, Miquel-Plaza J, Sanz-de-Villalobos E, Gonzalez-Mateos F, Parra T. Cytokines their pathogenic and therapeutic role in chronic viral hepatitis. *Rev Esp Enferm Dig.* 2009;**101**(5):343-51. doi: 10.4321/S1130-01082009000500006. [PubMed: 19527080].
- Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 2014;11:22. doi: 10.1186/1743-422X-11-22. [PubMed: 24507433].
- Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. *Aliment Pharmacol Ther*. 2015;**42**(3):243–57. doi: 10.1111/apt.13272. [PubMed: 26151841].
- Wang L, Zou ZQ, Liu CX, Liu XZ. Immunotherapeutic interventions in chronic hepatitis B virus infection: a review. J Immunol Methods. 2014;407:1–8. doi: 10.1016/j.jim.2014.04.004. [PubMed: 24747918].
- He D, Li M, Guo S, Zhu P, Huang H, Yan G, et al. Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. *J Clin Immunol.* 2013;33(7):1240–9. doi: 10.1007/s10875-013-9931-0. [PubMed: 23954997].
- Lian JQ, Yang XF, Zhao RR, Zhao YY, Li Y, Zhang Y, et al. Expression profiles of circulating cytokines, chemokines and immune cells in patients with hepatitis B virus infection. *Hepat Mon*. 2014;14(6). e18892. doi: 10.5812/hepatmon.18892. [PubMed: 24976843].
- Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. *J Hepatol.* 2010;**52**(3):330–9. doi: 10.1016/j.jhep.2009.12.015. [PubMed: 20137825].
- Ku LT, Gercel-Taylor C, Nakajima ST, Taylor DD. Alterations of T cell activation signalling and cytokine production by postmenopausal estrogen levels. *Immun Ageing*. 2009;6:1. doi: 10.1186/1742-4933-6-1. [PubMed: 19265538].
- Hyodo N, Tajimi M, Ugajin T, Nakamura I, Imawari M. Frequencies of interferon-gamma and interleukin-10 secreting cells in peripheral blood mononuclear cells and liver infiltrating lymphocytes in chronic hepatitis B virus infection. *Hepatol Res.* 2003;27(2):109–16. doi: 10.1016/S1386-6346(03)00199-2. [PubMed: 14563424].
- Poovorawan K, Tangkijvanich P, Chirathaworn C, Wisedopas N, Treeprasertsuk S, Komolmit P, et al. Circulating cytokines and histological liver damage in chronic hepatitis B infection. *Hepat Res Treat*. 2013;**2013**:757246. doi: 10.1155/2013/757246. [PubMed: 24288603].
- El-Kady IM, Lotfy M, Badra G, El-Masry S, Waked I. Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. *Scand J Immunol.* 2005;61(1):87-91. doi: 10.1111/j.0300-9475.2005.01529.x. [PubMed: 15644127].

- Biedermann T, Rocken M, Carballido JM. TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin. *J Investig Dermatol Symp Proc.* 2004;9(1):5–14. doi: 10.1111/j.1087-0024.2004.00829.x. [PubMed: 14870978].
- Sun QL, Ran W. Review of cytokine profiles in patients with hepatitis. World J Gastroenterol. 2004;10(12):1709–15. doi: 10.3748/wjg.v10.i12.1709. [PubMed: 15188491].
- Monsalve-De Castillo F, Romero TA, Estevez J, Costa LL, Atencio R, Porto L, et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. *Clin Diagn Lab Immunol.* 2002;9(6):1372-5. doi: 10.1128/CDLI.9.6.1372-1375.2002. [PubMed: 12414777].
- Penna A, Del Prete G, Cavalli A, Bertoletti A, D'Elios MM, Sorrentino R, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. *Hepatology*. 1997;25(4):1022–7. doi: 10.1002/hep.510250438. [PubMed: 9096614].
- Khan S, Bhargava A, Pathak N, Maudar KK, Varshney S, Mishra PK. Circulating Biomarkers and their Possible Role in Pathogenesis of Chronic Hepatitis B and C Viral Infections. *Indian J Clin Biochem.* 2011;26(2):161-8. doi: 10.1007/s12291-010-0098-7. [PubMed: 22468043].
- Ozguler M, Akbulut HH, Akbulut A. Evaluation of Interleukin-10 Levels in Patients Diagnosed with Chronic Hepatitis. West Indian Med J. 2015;64(2):71-5. doi: 10.7727/wimj.2014.154. [PubMed: 26360676].
- Saxena R, Chawla YK, Verma I, Kaur J. Association of interleukin-10 with hepatitis B virus (HBV) mediated disease progression in Indian population. *Indian J Med Res.* 2014;139(5):737–45. [PubMed: 25027084].
- Conde SR, Feitosa RN, Freitas FB, Hermes RB, Demachki S, Araujo MT, et al. Association of cytokine gene polymorphisms and serum concentrations with the outcome of chronic hepatitis B. *Cytokine*. 2013;61(3):940–4. doi: 10.1016/j.cyto.2013.01.004. [PubMed: 23395388].
- Dimitropoulou D, Karakantza M, Theodorou GL, Leonidou L, Assimakopoulos SF, Mouzaki A, et al. Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers. *World J Gastrointest Pathophysiol.* 2013;4(1):24-7. doi: 10.4291/wjgp.v4.i1.24. [PubMed: 23596552].
- Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol.

2005;11(21):3260-3. doi: 10.3748/wjg.v11.i21.3260. [PubMed: 15929178].

- Song le H, Binh VQ, Duy DN, Kun JF, Bock TC, Kremsner PG, et al. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. *J Clin Virol*. 2003;28(1):93-103. doi: 10.1016/S1386-6532(02)00271-8. [PubMed: 12927756].
- Jegaskanda S, Ahn SH, Skinner N, Thompson AJ, Ngyuen T, Holmes J, et al. Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen. *J Virol.* 2014;88(18):10412–20. doi: 10.1128/JVI.00111-14. [PubMed: 24872585].
- 31. Priimägi L, Tefanova V, Tallo T, Schmidt E. The role of serum Th1 and Th2 cytokines in patients with chronic hepatitis B and hepatitis C virus infection. *Acta Med Litu.* 2005;**12**(3):28–31.
- 32. Sofian M, Aghakhani A, Farazi AA, Banifazl M, Eslamifar A, Rashidi N, et al. Serum profile of Thelper 1 and Thelper 2 cytokines in hepatitis C virus infected patients. *Hepat Mon.* 2012;**12**(12). e6156. doi: 10.5812/hepatmon.6156. [PubMed: 23423691].
- Yalcin K, Degertekin H, Yildiz F, Celik Y. Markers of disease activity in chronic hepatitis B virus infection. *Clin Invest Med.* 2003;26(1):27–34. [PubMed: 12659467].
- Mohammadi M, Nejatollahi F. 3D structural modeling of neutralizing scFv against glycoprotein-D of HSV-1 and evaluation of antigenantibody interactions by bioinformatic methods. *Int J Pharm Bio Sci.* 2014;5(4):835–47.
- Moazen B, Ebrahimi E, Nejatollahi F. Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections. *Jundishapur J Microbiol*. 2016;9(3). e16241. doi: 10.5812/jjm.16241. [PubMed: 27217918].
- 36. Bagheri V, Nejatollahi F, Esmaeili SA, Momtazi AA, Motamedifar M, Sahebkar A. Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library. *Life Sci.* 2017;**169**:1–5. doi: 10.1016/j.lfs.2016.11.018. [PubMed: 27888111].
- Hashimoto M, Im SJ, Araki K, Ahmed R. Cytokine-Mediated Regulation of CD8 T-Cell Responses During Acute and Chronic Viral Infection. *Cold Spring Harb Perspect Biol*. 2017. doi: 10.1101/cshperspect.a028464. [PubMed: 29101105].
- Beltra JC, Decaluwe H. Cytokines and persistent viral infections. Cytokine. 2016;82:4-15. doi: 10.1016/j.cyto.2016.02.006. [PubMed: 26907634].